Findings from 4454 studies are being presented at the world's premier nephrology conference.
In a study, obese transplant recipients with low muscle mass had an increased risk of death but not graft loss.
The incidence of NODAT was 33.8% among patients who switched to everolimus and 36.4% among those who stayed on calcineurin inhibitors.
Opportunistic viral and fungal infections or malignancies develop in 34% of kidney transplant recipients, but these complications do not affect patient or graft survival.
In a study, diabetes in both the donor and recipient was associated with triple the risk of death at 5 years post-transplant compared with the absence of diabetes in both the donor and recipient.
Highest level of opioid use in the year prior to transplantation was associated with a 45% and 28% increased risk of death and graft loss, respectively.
Post-transplant UTI rates were lower when cephalexin was added to SMX-TMP than when SMX-TMP was used alone (7.5% vs 25.8%), study finds.
Kidney transplant recipients who experienced an episode of bacteremia had double the risks of graft failure and death.
Older patients with a Charlson Comorbidity Index score below 5 had a higher 3-year survival rate than those with a score of 5 or higher (90% vs 76%).
High-KDPI kidneys can improve the likelihood of a functioning graft compared with waiting for a superior kidney.
Venous thromboembolism is associated with a 4.1-fold increased risk of death and a 2.3-fold increased risk of death-censored graft loss among kidney transplant recipients.
Risk factors include impaired renal function and inadequate hydration prior to contrast exposure.
Angioplasty plus stenting is associated with less residual stenosis and a lower restenosis rate compared with angioplasty alone.
Researchers report that matching deceased kidney donors and kidney recipients by cytomegalovirus serostatus optimizes high- and low-risk profiles.
Five-year graft survival rates among recipients of kidneys from living donors increased from 76.6% in 1985-1894 to 85.4% in 2009-2015.
The adjusted 5-year risk of insulin use following donation is 5 times higher among obese vs normal weight donors.
In a study of renal transplant patients who received ureteral stents, ciprofloxacin did not lower the incidence of UTI compared with SMX-TMP.
As 25(OH)D levels increased, systolic blood pressure decreased significantly, even after accounting for calcium intake.
In a phase 2b trial, around half of patients taking the novel calcineurin inhibitor at a dose of 23.7 mg twice daily achieved complete remission at 48 weeks.
A patient experienced painful skin ulcers despite having normal renal function.
In a study, vonapanitase did not improve primary patency compared with placebo, but did improve secondary patency and fistula use for hemodialysis.
Significantly more patients treated with ferric citrate increased their hemoglobin levels by 1 g/dL or more over 8 weeks.
Adult patients with horseshoe kidneys have an estimated kidney stone incidence of 59%.
Among hemodialysis patients, sudden cardiac death accounted for 12% more cardiovascular-related mortalities in 2013 than in 2009.
Study demonstrates decreased risk of end-stage renal disease and all-cause mortality.
The prevalence of low hemoglobin levels increases with declining renal function.
ESRD patients aged 60-64 years with no insurance or who are on Medicaid are less likely to initiate peritoneal dialysis.
Nearly twice as many patients achieved the target phosphorus range after a year of taking the phosphate binder, regardless of iPTH level.
Ferric pyrophosphate citrate delivered via dialysate or intravenously rapidly donates iron to transferrin and is rapidly cleared from the circulation.
Nearly a quarter of hospitalizations are followed by readmission within 30 days for non-elective reasons.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)